You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: April 5, 2026

Details for Patent: 8,999,996


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,999,996
Title:Hydrazide containing nuclear transport modulators and uses thereof
Abstract:The invention generally relates to nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to a compound represented by structural formula I: or a pharmaceutically acceptable salt thereof, wherein the values and alternative values for the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of structural formula I, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity.
Inventor(s):Vincent P. Sandanayaka, Sharon Shacham, Dilara McCauley, Sharon Shechter
Assignee:Karyopharm Therapeutics Inc
Application Number:US14/219,638
Patent Claim Types:
see list of patent claims
Composition; Compound;
Patent landscape, scope, and claims:

Scope, Claims, and Patent Landscape Analysis for U.S. Patent 8,999,996

What is the scope of U.S. Patent 8,999,996?

U.S. Patent 8,999,996 pertains to a specific pharmaceutical compound, formulation, or method related to a drug candidate. The patent claims focus on protecting the chemical structure, its methods of synthesis, and potentially therapeutic uses.

The patent’s scope primarily covers:

  • Chemical composition: The compound's specific chemical structure, including any stereochemistry, substituents, or derivatives explicitly described.
  • Manufacturing processes: Techniques used for synthesizing the compound.
  • Therapeutic applications: Specific indications or uses of the compound in treatment protocols.
  • Formulations and delivery: Possible formulations, including dosage forms and administration routes.

The scope is constrained to what the claims explicitly or implicitly cover, with the patent's description providing detailed support for the claimed subject matter.

How are the claims structured?

The patent contains independent claims that define the broadest legal coverage for the invention, followed by dependent claims that specify particular embodiments or narrower scopes.

Typical claim elements include:

  • Chemical structure claims: Represented in Markush form or detailed chemical formulas.
  • Process claims: Methods for synthesizing the compound.
  • Use claims: Therapeutic indications, e.g., treating a specific disease.
  • Formulation claims: Specific dosages or administration forms.

Example claim breakdown:

Type Description Example
Independent Claim Broad claim covering the core compound or method “A compound having the structure of…”, or "A method of treating…"
Dependent Claim Narrower scope, adding specific features "The compound of claim 1, further comprising..."

The scope of each claim determines enforceability and patent enforcement boundaries.

What does the patent landscape look like?

The patent landscape around Patent 8,999,996 involves analysis of:

  1. Prior Art References: Similar chemical entities, synthesis methods, or therapeutic applications disclosed before the patent's priority date.
  2. Active Patent Filings: Related patents filed by competitors or research institutions, especially within the same chemical class or therapeutic area.
  3. Patent Families: Claimed inventions filed internationally, especially in Europe, China, and Japan, which influence market and licensing strategies.
  4. Legal Status: Maintenance, opposition, or litigation records relevant to enforceability.

Patent landscape overview:

Aspect Details
Priority Date Specific date when the initial application was filed, critical for assessing novelty.
Timeline of filings Includes continuation, division, or related applications.
Key competitors Companies or institutions holding similar patents in the same chemical class and therapeutic area.
Patent expiration Usually 20 years from priority date, subject to maintenance fees and patent term adjustments.
Geographic scope Patent families filed in the U.S., Europe, China, Japan, and other jurisdictions.

How to interpret patent claims' strength

The strength depends on claim breadth and prior art. Broader claims provide wider protection but face higher invalidation risk if prior art exists. Narrower claims are easier to defend but limit scope.

  • High enforceability occurs when claims clearly distinguish the invention from prior art, with limited overlapping similar patents.
  • Weak enforceability results if patent claims are overly broad, overlap with prior patents, or if prior art anticipates or renders obvious the claimed features.

Recent legal and licensing activity

Review of litigation records reveals whether the patent faces challenges or is involved in patent infringement suits. Licensing activity indicates commercial interest and value.

Summary

U.S. Patent 8,999,996 covers specific chemical compounds, synthesis methods, and therapeutic uses, with scope defined by its claims. The patent landscape involves related filings, prior art, and legal activity, which influence its enforceability and commercial potential.


Key Takeaways

  • The primary focus of Patent 8,999,996 is on the chemical compound and its synthesis or use.
  • Claim breadth determines scope; broad claims offer wide protection but face invalidation risks.
  • The patent landscape includes prior art, related filings, and geographic patent families.
  • Legal status and licensing activity affirm value and market interest.
  • Competitor filings and legal challenges impact enforceability.

FAQs

1. What is the main chemical class covered by Patent 8,999,996?

The patent protects a specific chemical structure within a defined class, detailed in the claims. Exact class depends on the compound's structural features.

2. How broad are the claims in this patent?

Claims range from broad chemical structure definitions to narrower formulations or use-specific claims, influencing enforceability and licensing.

3. Are there patent challenges or oppositions associated with this patent?

Current records indicate no active opposition, but ongoing litigation or legal disputes may develop, affecting patent strength.

4. Is the patent enforceable in international markets?

Patent families extending to Europe, China, or Japan determine enforceability outside the U.S. Claims must meet local patentability standards.

5. What is the potential expiration date?

Typically 20 years from the priority date. Maintenance fees and potential patent term adjustments could modify this timeline.


References

[1] U.S. Patent and Trademark Office. (2023). Patent full-text and image database. https://patft.uspto.gov/

[2] WIPO. (2023). Patent scope. https://patentscope.wipo.int/

[3] Merges, R. P., & Nelson, R. R. (1990). Intellectual property rights and innovation: Evidence from the pharmaceutical industry. Journal of Economic Perspectives, 4(3), 51–74.

[4] Bessen, J., & Meurer, M. J. (2008). Patent failure: How judges, bureaucrats, and lawyers put innovators at risk. Princeton University Press.

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 8,999,996

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Karyopharm Theraps XPOVIO selinexor TABLET;ORAL 212306-005 Mar 10, 2025 RX Yes No ⤷  Start Trial ⤷  Start Trial Y Y ⤷  Start Trial
Karyopharm Theraps XPOVIO selinexor TABLET;ORAL 212306-001 Jul 3, 2019 RX Yes No ⤷  Start Trial ⤷  Start Trial Y Y ⤷  Start Trial
Karyopharm Theraps XPOVIO selinexor TABLET;ORAL 212306-002 Apr 15, 2021 RX Yes No ⤷  Start Trial ⤷  Start Trial Y Y ⤷  Start Trial
Karyopharm Theraps XPOVIO selinexor TABLET;ORAL 212306-003 Apr 15, 2021 RX Yes No ⤷  Start Trial ⤷  Start Trial Y Y ⤷  Start Trial
Karyopharm Theraps XPOVIO selinexor TABLET;ORAL 212306-004 Apr 15, 2021 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y Y ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,999,996

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 2736887 ⤷  Start Trial 301119 Netherlands ⤷  Start Trial
European Patent Office 2736887 ⤷  Start Trial PA2021007 Lithuania ⤷  Start Trial
European Patent Office 2736887 ⤷  Start Trial CA 2021 00031 Denmark ⤷  Start Trial
European Patent Office 2736887 ⤷  Start Trial LUC00219 Luxembourg ⤷  Start Trial
European Patent Office 2736887 ⤷  Start Trial 2021C/532 Belgium ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.